Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder

NCT06788587 | Recruiting Phase 2 DMC

• 1 other identifier: 2025_12643
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

Methamphetamine use disorder (MUD) is becoming an increasing public health concern in Canada. While the evidence on the efficacy and safety of prescription psychostimulants for the treatment of MUD is promising, the knowledge on the maintenance therapy using stimulant agonist therapy is scarce and needs further investigation, especially in terms of long-term retention in treatment. The goal of this clinical trial is to evaluate the feasibility of a long-term (25 weeks) administration of high-dose stimulant agonist therapy, using Lisdexamfetamine (LDX-01) on top of treatment-as-usual (TAU), in a population of people with moderate to severe MUD, as measured by study retention, treatment retention, treatment adherence and satisfaction compared against a placebo group. Participants will be placed randomly into one of two groups:

1. 1.TAU and high-dose LDX-01
2. 2.TAU and placebo

Conditions

Methamphetamine Abuse; Methamphetamine-dependence; Addiction; Substance Abuse; Methamphetamine Use Disorder

Keywords

Substance use disorder; Amphetamines; Methamphetamine; Lisdexamfetamine; Treatment; Agonist therapy; Feasibility

Outcome Measures

Primary Outcomes (4)

• Retention in treatment

  Retention in treatment will be measured as the proportion of study participants who receive any intervention during the 4 weeks before week 22 and 4 weeks before week 26

  Weeks 18, 19, 20, 21 and weeks 22, 23, 24, 25

• Treatment satisfaction

  Participant treatment satisfaction will be measured by evaluating participant satisfaction using the Client Satisfaction Questionnaire-8 (CSQ-8) questionnaire. The total score ranges from 8 (minimum) to 32 (maximum) with the higher values showing greater satisfaction.

  Weeks 22, 26

• Retention in study

  Retention in study will be measured as 1) the proportion of study participants who return for the study visit at week 22 with or without receiving the study interventions, 2) the proportion of study participants who return for the study visit at week 26 with or without receiving the study interventions, and 3) the proportion of study participants who return for the last study visit at week 30 with or without receiving the study interventions.

  Weeks 22, 26 and 30

• Treatment adherence

  Treatment adherence will be first, measured individually, as the total proportion of the number of the assigned medications (LDX-01/placebo) taken through the intervention (from baseline until the end of week 25) and then averaged across all study completers.

  from week 1 day 1 to week 25

Other Outcomes (7)

• Safety events

  up to 30 weeks : from the date of enrollment until week 30

• QTc measurement

  Screening, weeks 1, 2, 3, 7 and 22

• Self-reported methamphetamine use

  Baseline, week 1 day 1, weeks 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 26 and 30

Study Arms (2)

LDX-01 + TAU

EXPERIMENTAL

Participants will receive TAU at the clinic as well as once daily over-encapsulated LDX-01 orally for 25 weeks.

Drug: LDX-01 plus TAU

Placebo + TAU

PLACEBO COMPARATOR

Participants will receive TAU at the clinic as well as once daily LDX-01-matched placebo orally for 25 weeks.

Drug: Placebo plus TAU

Interventions

LDX-01 plus TAU DRUG

Participants receive once daily LDX-01 for 25 weeks, as well as TAU at a clinical site. Medication is provided in 3 phases: Week 1 (Induction Phase): 100 mg (Days 1 and 2), 150 mg (Days 3 and 4), 200 mg (Days 5, 6 and 7); Weeks 2-21 (Maintenance Phase): 250 mg (or the maximum tolerated for each individual) ; Weeks 22-25 (Taper Phase): 200 mg (Week 22), 150 mg (Week 23), 100 mg (Week 24) and 50 mg (Week 25).

LDX-01 + TAU

Placebo plus TAU DRUG

Participants receive once daily LDX-01-matched placebo for 25 weeks, as well as TAU at a clinical site. Medication is provided in 3 phases: Week 1 (Induction Phase): 100 mg (Days 1 and 2), 150 mg (Days 3 and 4), 200 mg (Days 5, 6 and 7); Weeks 2-21 (Maintenance Phase): 250 mg (or the maximum tolerated for each individual) ; Weeks 22-25 (Taper Phase): 200 mg (Week 22), 150 mg (Week 23), 100 mg (Week 24) and 50 mg (Week 25).

Placebo + TAU

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Between 18 and 55 years of age at enrollment in the parent ASCME trial;
• Diagnosed with a moderate to severe MUD as defined by the DSM-5 criteria;
• Enrolled in the parent ASCME trial and completed the study up to and including the end of study visit at Week 20, Day 1;
• Interested in avoiding relapse, decreasing methamphetamine use, or abstaining from methamphetamine use;
• Presence of ongoing substance use, craving, or significant risk of relapse that according to the study physician, warrants extended treatment for MUD;
• If female:
• Be of non-childbearing potential, defined as (i) postmenopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age); or (ii) documented surgically sterilized (i.e., tubal ligation, hysterectomy, or bilateral oophorectomy); or
• Be of childbearing potential, have a negative pregnancy test at screening, and agree to use an acceptable method of birth control throughout the study;
• Willing to be randomized to one of 2 study arms and followed for the duration of the trial;
• Able to start the study intervention within 28 days after completing the ASCME main trial (study no. CRISM-002);
• Able to provide informed consent;
• Willing to comply with study procedures;
• Able to communicate in English or French

You may not qualify if:

• Symptomatic or advanced cardiovascular disease (e.g., advanced arteriosclerosis), moderate hypertension; confirmed current hyperthyroidism; known hypersensitivity or idiosyncrasy to the sympathomimetic amines or glaucoma or any disabling, severe, or unstable medical condition (including electrolyte disturbances) that, in the opinion of the study physician, precludes safe participation or the ability to provide fully informed consent;
• Any severe or unstable co-morbid substance use disorder that, in the opinion of the study physician, precludes safe participation in the study;
• Participants with Opioid Use Disorder (OUD) who have been on Opioid Agonist Treatment (OAT) for \<12 weeks, and not yet at stabilization dose, or at stabilization dose \<4 weeks;
• Current or a history of any serious psychiatric disorder (e.g., bipolar disorder, pre-existing psychosis, schizophrenia) that, in the opinion of the study physician, precludes safe participation in the study;
• History of a SAE, hypersensitivity or known allergic reaction to LDX-01 or other amphetamine drugs, or hypersensitivity to the sympathomimetic amines;
• Pregnant, nursing, or planning to become pregnant during the study period;
• Planned extended absence during the study period (e.g., pending legal action, surgery, incarceration, inpatient residential program) in the opinion of the study physician that might prevent completion of the study;
• Use of an investigational drug for stimulant use disorder during the 30 days before screening, confirmed via self-report or pharmacy records; excluding the use of study medication in the parent ASCME trial;
• Use of prescribed amphetamine-type medication or medication for the treatment of stimulant use disorder (e.g., methylphenidate, modafinil, bupropion, or mirtazapine) in the 4 weeks before screening;
• Current or anticipated need for treatment with any medication that may interact with LDX-01 (e.g., monoamine oxidase inhibitors \[MAOIs\]) used currently or within the past 14 days and that would preclude study participant at the discretion of the study physician;
• ECG measurement (Bazett method for the correction of QT interval) that indicates a prolonged QTc interval (≥460 milliseconds for females and ≥450 milliseconds for males) at screening;
• Any SAEs related to the study product in the parent trial phase that, in the opinion of the study physician, precludes safe participation in the extension study;
• Any compliance issues related to the study product and/or study procedures during the parent trial phase that, in the opinion of the study physician, precludes safe participation in the extension study.

Sponsors & Collaborators

• Centre hospitalier de l'Université de Montréal (CHUM): lead
• Ministere de la Sante et des Services Sociaux: collaborator
• Health Canada: collaborator

Study Sites (1)

Centre hospitalier de l'Université de Montréal (CHUM)

Montreal, Quebec, H2X 0A9, Canada

RECRUITING

MeSH Terms

Conditions

Behavior, Addictive; Substance-Related Disorders

Condition Hierarchy (Ancestors)

Compulsive Behavior; Impulsive Behavior; Behavior; Chemically-Induced Disorders; Mental Disorders

Study Officials

• Didier Jutras-Aswad, MD

  CHUM

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Devon Blanchette

CONTACT

780-953-6630; dblanchette@changemark.ca

Amina Sow, Ph.D

CONTACT

438-860-2452; amina.sow.chum@ssss.gouv.qc.ca

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Single-centre, 2-arm, randomized, double-blind, dose-ascending, placebo-controlled extension trial. Participants will be enrolled into one of 2 treatment arms: * Arm 1: LDX-01 + TAU * Arm 2: Placebo + TAU

Study Record Dates

• First Submitted: January 10, 2025
• First Posted: January 23, 2025
• Study Start: July 18, 2025
• Primary Completion (Estimated): August 1, 2027
• Study Completion (Estimated): December 1, 2027
• Last Updated: February 23, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)